Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 25/100

Termination Rate

0.0%

0 terminated out of 5 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

3Total
P 2 (3)

Trial Status

Recruiting2
Unknown1
Active Not Recruiting1
Completed1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 1 completed trials

Clinical Trials (5)

Showing 5 of 5 trials
NCT04938232Phase 2Active Not Recruiting

Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL

NCT05346809Phase 2Recruiting

Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma

NCT05595447Phase 2Recruiting

Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

NCT04776265Unknown

RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCT

NCT04464590Completed

Interest of a Systematic One-year Monitoring by 18F-FDG PET-CT

Showing all 5 trials

Research Network

Activity Timeline